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MorpholineAbstract A variety of novel isatin derivatives 5a–5j and 6a–6j were synthesized and characterized
by spectroscopic means and elemental analysis. The title compounds were investigated for antiep-
ileptic activity using MES and scPTZ seizures tests. Neurotoxicity study was performed by the roto-
rod test. The relationship between the functional group variation and the biological activity of the
evaluated compounds was discussed. Among the synthesized analogs, the most active one was 6f
that revealed protection in MES at a dose of 30 mg/kg (i.p.) after 0.5 h and 4 h. This molecule also
provided protection in the scPTZ at a dose of 100 mg/kg (0.5 h) and 300 mg/kg (4 h).
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Epilepsy is one of the more common brain disorders charac-
terized by recurrent spontaneous seizures of cerebral origin,
presenting with episodes of sensory, motor or autonomic phe-
nomenon with or without loss of consciousness.1 About 1%
of the world population has epilepsy, with almost 90% of
these people being in developing countries.2 Epilepsy alsoaffects about 5% of individuals over their life time. In fact,
epilepsy is the 3rd most often spread neurological disorder
identiﬁed in the elderly after dementia and cerebrovascular
diseases.3 Currently a signiﬁcant group of patients are resis-
tant to the available antiepileptic drugs (AEDs), hence there
is a need for improved agents for the treatment of seizure dis-
orders. Moreover, many AEDs have serious side effects such
as ataxia, drowsiness, gingival hyperplasia, gastrointestinal
disturbances, and megaloblastic anemia.4,5 These limitations
with current AEDs demands the necessity of the development
of more selective and lower toxic AEDs in the ﬁeld of medic-
inal chemistry.
Many studies revealed that isatin is a privileged lead mole-
cule for scheming potential bioactive agents, and their deriva-
tives constitute an important class of heterocyclic compounds
and are shown to possess a broad spectrum of bioactivity.6–12
These exciting properties encouraged many efforts toward the
116 G. Saravanan et al.synthesis and pharmacological screening of many isatin deriv-
atives. On the other hand, several studies have identiﬁed isox-
azoles as a structurally novel class of compounds with various
biological activities.13,14
The conformational analysis of well established AEDs
(Fig. 1) showed that for anticonvulsant activity, the model
must be comprised of (i) hydrogen acceptor/donor unit
(HAD), (ii) one electron donor atom (D) and (iii) a hydropho-
bic domain (A) (aryl ring substituted/unsubstituted).15,16
Motivated by the aforementioned ﬁndings and considering
the wide applications of isatin molecule in medicinal chemistry
an attempt has been made to synthesize novel 1-(morpholi-
nomethyl)-3-substituted isatin moiety as new antiepileptic
agents.
2. Materials and methods
2.1. Chemistry
All solvents used were of laboratory grade and were obtained
from SD ﬁne chemicals (Mumbai, India), and Merck (Mum-
bai, India). Ciproﬂoxacin and Ketoconazole are received as
gift samples from Dr. Reddys laboratories, Hyderabad, India.
Melting points were determined in open glass capillary tubes






























































Figure 1 Pharmacophoric pattern of well known antiepileptics and m
aryl ring system, (HAD) hydrogen bond acceptor/donor domain, andtheir purity on Silica gel G (Merck) Thin layer chromatogra-
phy (TLC) plates using ethyl acetate: methanol: toluene
(40:30:30) as elevator system; iodine chamber and UV lamp
were used for visualization of TLC spots. The IR spectra were
recorded in KBr pellets on (BIO-RAD FTS) FT-IR spectro-
photometer. NMR spectra were recorded on Bruker Avance-
300 NMR spectrometer in CDCl3 using tetramethylsilane
(TMS) for 1H NMR and CDCl3 for
13C NMR as an internal
standard. The chemical shifts are reported in ppm scale. Mass
spectra were obtained on a JEOL-SX-102 instrument using
electron impact ionization. Elemental analyses were performed
on a Perkine Elmer model 2400 CHN analyzer and were within
±0.4% of the theoretical values.
2.1.1. Synthesis of isonitrosoacetanilide (1)
Isatin was synthesized from aniline through isonitrosoacetani-
lide by the reported method.17,18 Chloral hydrate (4.5 g;
0.027 mol) was dissolved in water (60 ml). To this solution
crystallized sodium sulfate (6.5 g), solution of aniline (2.3 g;
0.025 mol) in water (15 ml), and concentrated hydrochloric
acid (2.56 g; 0.026 mol) were added in order to dissolve the
amine. To this hydroxylamine hydrochloride (5.5 g;
0.079 mol) dissolved in water (25 ml) was added. The ﬂask
was heated over a wire gauze by a burner for about 40–





















































Model compound structure (6a-6j)
D
odel compound with its vital structural features: (A) hydrophobic
(D) electron donor moiety.
Novel isatin derivatives 117completed. During heating some crystals of isonitrosoacetani-
lide 1 were separated. On cooling, the solution in running
water, the remainder was crystallized. It was ﬁltered and air
dried. Yield 72%; m.p. 173–175 C.
2.1.2. Synthesis of isatin (2)
Concentrated sulfuric acid (16.3 ml) was heated at 50 C. To
this dry isonitrosoacetanilide 1 (3.75 g; 0.023 mol) was added
at such a rate as to keep the temperature between 60 and
70 C but not higher. External cooling should be applied at
this stage to carry out the reaction more rapidly. After com-
plete addition of isonitrosoacetanilide 1 the solution was
heated at 80 C and kept at this temperature for about
10 min to complete the reaction. Then the mixture was cooled
to room temperature and was poured to 10–12 times its vol-
ume of crushed ice. After standing for 2 h, the isatin was ﬁl-
tered with suction, washed several times with cold water to
remove sulfuric acid. It was then ﬁltered, dried and recrystal-
lised. Yield 75%; m.p. 189–192 C.
2.1.3. Synthesis of 3-(4-acetylphenylimino)indolin-2-one (3)
Isatin 2 (1.47 g, 0.01 mol) and p-amino acetophenone (1.33 g,
0.01 mol) was taken in round bottomed ﬂask and dissolved
in ethanol (15 ml). The above mixture was reﬂuxed on a water
bath for 6 h. The resulting solution was cooled to room tem-
perature and poured into crushed ice. Then the solution was
kept overnight in room temperature. The separated product
was ﬁltered and dried in air. The obtained product was recrys-
tallised using alcohol. Yield 70%, m.p. 113–115 C. IR (KBr
cm1): 3359 (NH), 3066 (ArACH), 2918 (CH3ACH), 1712
(C‚O), 1575 (C‚N), 1074 (CAOAC). 1H NMR (CDCl3,
300 MHz) d ppm: 3.15 (s, 3H, COCH3), 6.91–8.03 (m, 8H,
ArACH), 8.89 (s, 1H, NH of isatin). 13C NMR (CDCl3,
300 MHz) d ppm: 32.6 (CH3), 112.3 (C-9), 120.9 (C-7), 121.5
(C0-2 and C0-6), 125.8 (C-5), 130.2 (C-4), 131.7 (C0-3 and C0-
5), 133.6 (C-6), 139.9 (C0-4), 145.4 (C-8), 159.2 (C0-1), 167.1
(C-3), 170.6 (C-2), 204.3 (C‚O). MS (EI): m/z 264 [M+];
Anal. Cald for C16H12N2O2: C, 72.72; H, 4.58; N, 10.60.
Found: C, 72.60; H, 4.59; N, 10.63.
2.1.4. Synthesis of 3-(4-acetylphenylimino)-1-(morpholinom-
ethyl)indolin-2-one (4)
A mixture of 3-(4-acetylphenylimino)indolin-2-one 3 (1.85 g,
0.007 mol), formaldehyde (0.3 g, 0.01 mol) and morpholine
(0.6 g, 0.007 mol) in ethanol (20 ml) was stirred for the period
of 1 h. The mixture was then reﬂuxed for 4 h. Then the reac-
tion mixture was cooled and poured in ice cold water. The ob-
tained product was ﬁltered and recrystallised using ethanol.
Yield 78%, m.p. 96–98 C. IR (KBr cm1): 3091 (ArACH),
2936 (CH3ACH), 1747 (C‚O), 1539 (C‚N), 1062 (CAOAC).
1H NMR (CDCl3, 300 MHz) d ppm: 1.92–2.87 (t, 4H, CH2 of
morpholine), 3.23 (s, 3H, COCH3), 3.65–4.39 (t, 4H, CH2 of
morpholine), 4.80 (s, 2H, NCH2N), 7.17–8.25 (m, 8H,
ArACH). 13C NMR (CDCl3, 300 MHz) d ppm: 34.1 (CH3),
54.8 (C00-2 and C00-6), 69.3 (C00-3 and C00-5), 72.0 (CH2),
114.6 (C-9), 122.7 (C-7), 123.1 (C0-2 and C0-6), 127.2 (C-5),
130.5 (C-4), 132.5 (C0-3 and C0-5), 136.0 (C-6), 138.4 (C0-4),
147.8 (C-8), 155.6 (C0-1), 164.2 (C-3), 165.9 (C-2), 198.1
(C‚O). MS (EI): m/z 363 [M+]. Anal. Cald for
C21H21N3O3: C, 69.41; H, 5.82; N, 11.56. Found: C, 69.55;
H, 5.80; N, 11.53.2.1.5. Synthesis of 1-(morpholinomethyl)-3-(4-(3-
substitutedacryloyl)phenylimino)indolin-2-one (5a–5j)
A mixture of 3-(4-acetylphenylimino)-1-(morpholinometh-
yl)indolin-2-one 4 (1.09 g, 0.003 mol), different aromatic/
heterocyclic aldehydes (0.003 mol) and sodium hydroxide pel-
lets (100 mg) in ethanol (20 ml) was stirred magnetically for
1 h. Then the reaction mixture was reﬂuxed for about 4 h.
Then the resulting solution was poured into crushed ice and
kept in a refrigerator overnight. The separated product was ﬁl-
tered, dried and crystallized from ethanol.
2.1.5.1. 1-(Morpholinomethyl)-3-(4-(3-phenylacryloyl)phenyli-
mino)indolin-2-one (5a). Yield 73%, m.p. 193–195 C. IR
(KBr cm1): 3054 (ArACH), 1726 (C‚O), 1550 (C‚N),
1052 (CAOAC). 1H NMR (CDCl3, 300 MHz) d ppm: 2.38–
3.03 (t, 4H, CH2 of morpholine), 3.10–3.77 (t, 4H, CH2 of
morpholine), 4.59 (s, 2H, NCH2N), 7.01–7.95 (m, 13H,
ArACH), 8.14–8.39 (m, 2H, CH‚CH). 13C NMR (CDCl3,
300 MHz) d ppm: 50.3 (C00-2 and C00-6), 70.7 (C00-3 and C00-
5), 73.9 (CH2), 119.1 (C-9), 124.8 (CH‚CH), 125.0 (C-7),
127.6 (C0-2 and C0-6), 129.9 (C-5), 130.1 (C000-2 and C000-6),
132.8 (C000-4), 133.2 (C000-3 and C000-5), 134.3 (C-4), 135.0 (C0-3
and C0-5), 136.5 (C-6), 137.2 (C000-1), 138.9 (C0-4), 145.8
(CH‚CH), 147.1 (C-8), 153.4 (C0-1), 160.7 (C-3), 161.9 (C-
2), 192.6 (C‚O). MS (EI): m/z 451 [M+]. Anal. Cald for
C28H25N3O3: C, 74.48; H, 5.58; N, 9.31. Found: C, 74.65; H,
5.57; N, 9.28.
2.1.5.2. 1-(Morpholinomethyl)-3-(4-(3-p-tolylacryloyl)phenyli-
mino)indolin-2-one (5b). Yield 78%, m.p. 215–217 C. IR
(KBr cm1): 3081 (ArACH), 2920 (CH3ACH), 1738 (C‚O),
1563 (C‚N), 1075 (CAOAC). 1H NMR (CDCl3, 300 MHz)
d ppm: 1.95–2.72 (t, 4H, CH2 of morpholine), 3.09 (s, 3H,
CH3), 3.36–3.80 (t, 4H, CH2 of morpholine), 4.25 (s, 2H,
NCH2N), 6.87–7.74 (m, 12H, ArACH), 7.91–8.27 (m, 2H,
CH‚CH). 13C NMR (CDCl3, 300 MHz) d ppm: 26.4 (CH3),
52.5 (C00-2 and C00-6), 68.4 (C00-3 and C00-5), 72.7 (CH2),
116.5 (C-9), 120.2 (CH‚CH), 121.6 (C-7), 124.3 (C0-2 and
C0-6), 126.8 (C-5), 128.6 (C000-2 and C000-6), 132.0 (C000-3 and
C000-5), 133.1 (C-4), 134.5 (C0-3 and C0-5), 136.2 (C-6), 137.0
(C000-1), 139.5 (C0-4), 140.1 (C000-4), 147.3 (CH‚CH), 148.6
(C-8), 160.8 (C0-1), 164.5 (C-3), 165.7 (C-2), 187.4 (C‚O).
MS (EI): m/z 465 [M+]. Anal. Cald for C29H27N3O3: C,
74.82; H, 5.85; N, 9.03. Found: C, 74.99; H, 5.86; N, 9.00.
2.1.5.3. 1-(Morpholinomethyl)-3-(4-(3-(4-nitrophenyl)acry-
loyl)phenylimino)indolin-2-one (5c). Yield 81%, m.p. 209–
212 C. IR (KBr cm1): 3106 (ArACH), 1714 (C‚O), 1531
(C‚N), 1506 and 1319 (NO2), 1067 (CAOAC).
1H NMR
(CDCl3, 300 MHz) d ppm: 2.14–2.87 (t, 4H, CH2 of morpho-
line), 3.02–3.95 (t, 4H, CH2 of morpholine), 4.71 (s, 2H,
NCH2N), 6.65–7.83 (m, 12H, ArACH), 8.02–8.30 (m, 2H,
CH‚CH). 13C NMR (CDCl3, 300 MHz) d ppm: 50.7 (C00-2
and C00-6), 64.9 (C00-3 and C00-5), 75.5 (CH2), 120.2 (C-9),
125.8 (C000-3 and C000-5), 126.6 (CH‚CH), 127.2 (C-7), 129.0
(C0-2 and C0-6), 130.6 (C-5), 135.3 (C000-2 and C000-6), 138.2
(C-4), 139.8 (C0-3 and C0-5), 140.6 (C-6), 142.1 (C0-4), 145.7
(C000-1), 148.4 (CH‚CH), 149.5 (C000-4), 149.7 (C-8), 157.2
(C0-1), 161.8 (C-3), 162.1 (C-2), 191.3 (C‚O). MS (EI): m/z
496 [M+]. Anal. Cald for C28H24N4O5: C, 67.73; H, 4.87; N,
11.28. Found: C, 67.51; H, 4.88; N, 11.31.
118 G. Saravanan et al.2.1.5.4. 3-(4-(3-(4-Methoxyphenyl)acryloyl)phenylimino)-1-
(morpholinomethyl)indolin-2-one (5d). Yield 74%, m.p. 180–
182 C. IR (KBr cm1): 3029 (ArACH), 2905 (CH3ACH),
1752 (C‚O), 1576 (C‚N), 1054 (CAOAC). 1H NMR
(CDCl3, 300 MHz) d ppm: 2.49–2.90 (t, 4H, CH2 of morpho-
line), 3.15 (s, 3H, OCH3), 3.28–3.84 (t, 4H, CH2 of morpho-
line), 4.36 (s, 2H, NCH2N), 6.92–7.99 (m, 12H, ArACH),
8.15–8.41 (m, 2H, CH‚CH). 13C NMR (CDCl3, 300 MHz)
d ppm: 54.2 (C00-2 and C00-6), 56.1 (OCH3), 69.8 (C00-3 and
C00-5), 73.3 (CH2), 110.0 (C000-3 and C000-5), 119.7 (C-9), 123.2
(CH‚CH), 124.0 (C-7), 124.9 (C0-2 and C0-6), 127.1 (C-5),
129.5 (C000-2 and C000-6), 131.4 (C000-1), 132.0 (C-4), 132.8 (C0-3
and C0-5), 133.6 (C-6), 137.3 (C0-4), 143.9 (CH‚CH), 148.2
(C-8), 155.7 (C0-1), 159.0 (C000-4), 167.5 (C-3), 167.9 (C-2),
185.2 (C‚O). MS (EI): m/z 481 [M+]. Anal. Cald for
C29H27N3O4: C, 72.33; H, 5.65; N, 8.73. Found: C, 72.12; H,
5.67; N, 8.75.
2.1.5.5. 3-(4-(3-(4-Hydroxyphenyl)acryloyl)phenylimino)-1-
(morpholinomethyl)indolin-2-one (5e). Yield 72%, m.p. 158–
160 C. IR (KBr cm1): 3513 (OH), 2997 (ArACH), 1734
(C‚O), 1549 (C‚N), 1061 (CAOAC). 1H NMR (CDCl3,
300 MHz) d ppm: 2.01–2.75 (t, 4H, CH2 of morpholine),
2.99–3.67 (t, 4H, CH2 of morpholine), 4.16 (s, 2H, NCH2N),
5.63 (s, 1H, OH), 6.78–7.60 (m, 12H, ArACH), 7.82–8.14
(m, 2H, CH‚CH). 13C NMR (CDCl3, 300 MHz) d ppm:
49.8 (C00-2 and C00-6), 70.4 (C00-3 and C00-5), 76.2 (CH2),
115.5 (C000-3 and C000-5), 118.7 (C-9), 120.0 (CH‚CH), 122.9
(C-7), 125.3 (C0-2 and C0-6), 126.2 (C-5), 130.8 (C000-2 and
C000-6), 131.9 (C000-1), 132.4 (C-4), 134.7 (C0-3 and C0-5), 135.3
(C-6), 139.1 (C0-4), 147.6 (CH‚CH), 150.3 (C-8), 155.5 (C000-
4), 158.9 (C0-1), 161.2 (C-3), 161.6 (C-2), 192.4 (C‚O). MS
(EI): m/z 467 [M+]. Anal. Cald for C28H25N3O4: C, 71.93;
H, 5.39; N, 8.99. Found: C, 71.75; H, 5.41; N, 9.02.
2.1.5.6. 3-(4-(3-(4-(Dimethylamino)phenyl)acryloyl)phenyli-
mino)-1-(morpholinomethyl) indolin-2-one (5f). Yield 79%,
m.p. 173–175 C. IR (KBr cm1): 3061 (ArACH), 2947 (CH3-
ACH), 1749 (C‚O), 1554 (C‚N), 1056 (CAOAC). 1H NMR
(CDCl3, 300 MHz) d ppm: 1.87–2.59 (t, 4H, CH2 of morpho-
line), 3.04 (s, 6H, N(CH3)2), 3.20–3.85 (t, 4H, CH2 of morpho-
line), 4.32 (s, 2H, NCH2N), 7.19–8.06 (m, 12H, ArACH),
8.20–8.47 (m, 2H, CH‚CH). 13C NMR (CDCl3, 300 MHz)
d ppm: 43.4 (N[CH3]2), 52.7 (C00-2 and C00-6), 65.2 (C00-3 and
C00-5), 72.5 (CH2), 113.9 (C000-3 and C000-5), 119.1 (C-9), 122.4
(CH‚CH), 123.0 (C-7), 124.8 (C0-2 and C0-6), 125.3 (C-5),
126.2 (C000-1), 127.5 (C000-2 and C000-6), 130.6 (C-4), 132.9 (C0-3
and C0-5), 133.4 (C-6), 135.0 (C0-4), 143.7 (CH‚CH), 146.4
(C-8), 150.1 (C000-4), 162.8 (C0-1), 166.3 (C-3), 167.0 (C-2),
187.5 (C‚O). MS (EI): m/z 494 [M+]. Anal. Cald for
C30H30N4O3: C, 72.85; H, 6.11; N, 11.33. Found: C, 73.09;
H, 6.09; N, 11.30.
2.1.5.7. 1-(Morpholinomethyl)-3-(4-(3-(3-nitrophenyl)acry-
loyl)phenylimino)indolin-2-one (5g). Yield 76%, m.p. 199–
201 C. IR (KBr cm1): 3093 (ArACH), 1716 (C‚O),
1578 (C‚N), 1540 and 1333 (NO2), 1065 (CAOAC).
1H
NMR (CDCl3, 300 MHz) d ppm: 2.26–2.94 (t, 4H, CH2 of
morpholine), 3.27–3.90 (t, 4H, CH2 of morpholine), 4.52
(s, 2H, NCH2N), 6.83–7.98 (m, 12H, ArACH), 8.18–8.45
(m, 2H, CH‚CH). 13C NMR (CDCl3, 300 MHz) d ppm:
57.7 (C00-2 and C00-6), 64.1 (C00-3 and C00-5), 69.4 (CH2),116.6 (C-9), 123.9 (C000-4), 125.0 (C000-6), 125.6 (CH‚CH),
126.4 (C-7), 127.1 (C0-2 and C0-6), 128.3 (C-5), 129.8 (C-
4), 130.0 (C000-3), 134.4 (C0-3 and C0-5), 135.7 (C-6), 136.5
(C000-2), 139.1 (C000-1), 139.8 (C0-4), 149.3 (CH‚CH), 150.6
(C-8), 152.9 (C000-5), 157.2 (C0-1), 162.8 (C-3), 163.4 (C-2),
194.7 (C‚O). MS (EI): m/z 496 [M+]. Anal. Cald for
C28H24N4O5: C, 67.73; H, 4.87; N, 11.28. Found: C,
67.98; H, 4.86; N, 11.24.
2.1.5.8. 3-(4-(3-(2-Chlorophenyl)acryloyl)phenylimino)-1-
(morpholinomethyl)indolin-2-one (5h). Yield 72%, m.p. 221–
223 C. IR (KBr cm1): 3068 (ArACH), 1761 (C‚O), 1535
(C‚N), 1063 (CAOAC), 744 (Cl). 1H NMR (CDCl3,
300 MHz) d ppm: 2.02–2.77 (t, 4H, CH2 of morpholine),
2.91–3.64 (t, 4H, CH2 of morpholine), 4.09 (s, 2H, NCH2N),
6.68–7.85 (m, 12H, ArACH), 7.93–8.26 (m, 2H, CH‚CH).
13C NMR (CDCl3, 300 MHz) d ppm: 52.4 (C00-2 and C00-6),
66.8 (C00-3 and C00-5), 70.9 (CH2), 118.0 (C-9), 123.5
(CH‚CH), 123.8 (C-7), 125.3 (C0-2 and C0-6), 126.6 (C-5),
129.1 (C000-5), 130.7 (C000-6), 131.5 (C000-3), 132.2 (C000-4), 133.0
(C-4), 135.8 (C0-3 and C0-5), 136.4 (C000-2), 136.9 (C-6), 137.5
(C000-1), 139.0 (C0-4), 144.3 (CH‚CH), 146.1 (C-8), 161.6
(C0-1), 164.9 (C-3), 165.5 (C-2), 184.2 (C‚O). MS (EI): m/z
487 [M+2]. Anal. Cald for C28H24ClN3O3: C, 69.20; H, 4.98;
N, 8.65. Found: C, 69.44; H, 4.97; N, 8.63.
2.1.5.9. 1-(Morpholinomethyl)-3-(4-(5-phenylpenta-2,4-die-
noyl)phenylimino)indolin-2-one (5i). Yield 78%, m.p. 206–
208 C. IR (KBr cm1): 2993 (ArACH), 1720 (C‚O), 1552
(C‚N), 1076 (CAOAC). 1H NMR (CDCl3, 300 MHz) d
ppm: 1.98–2.60 (t, 4H, CH2 of morpholine), 2.85–3.41 (t,
4H, CH2 of morpholine), 4.37 (s, 2H, NCH2N), 7.19–8.22
(m, 13H, ArACH), 8.33–8.98 (m, 4H, CH‚CH). 13C NMR
(CDCl3, 300 MHz) d ppm: 50.2 (C00-2 and C00-6), 69.7 (C00-3
and C00-5), 71.4 (CH2), 116.9 (C-9), 121.1 (C-7), 122.5 (C0-2
and C0-6), 123.8 (C-5), 125.3 (CH‚CH-CH‚CH), 126.9
(C000-2 and C000-6), 129.0 (C000-4), 129.4 (C000-3 and C000-5), 129.7
(CH‚CHACH‚CH), 130.1 (C-4), 132.5 (C0-3 and C0-5),
133.0 (CH‚CHACH‚CH), 133.6 (C-6), 136.2 (C000-1), 136.8
(C0-4), 146.5 (CH‚CHACH‚CH), 149.0 (C-8), 162.7 (C0-
1), 163.1 (C-3), 163.9 (C-2), 188.4 (C‚O). MS (EI): m/z 477
[M+]. Anal. Cald for C30H27N3O3: C, 75.45; H, 5.70; N,
8.80. Found: C, 75.23; H, 5.72; N, 8.83.
2.1.5.10. 3-(4-(3-(Furan-2-yl)acryloyl)phenylimino)-1-(mor-
pholinomethyl)indolin-2-one (5j). Yield 75%, m.p. 187–
189 C. IR (KBr cm1): 3040 (ArACH), 1703 (C‚O),
1547 (C‚N), 1055 (CAOAC). 1H NMR (CDCl3,
300 MHz) d ppm: 2.45–2.94 (t, 4H, CH2 of morpholine),
3.32–3.98 (t, 4H, CH2 of morpholine), 4.65 (s, 2H, NCH2-
N), 6.51–7.06 (m, 3H, CH of furan), 7.25–7.93 (m, 8H,
ArACH), 8.06–8.27 (m, 2H, CH‚CH). 13C NMR (CDCl3,
300 MHz) d ppm: 55.5 (C00-2 and C00-6), 68.2 (C00-3 and C00-
5), 71.7 (CH2), 110.4 (C
000-3), 112.9 (C000-4), 116.6 (C-9),
120.3 (C-7), 123.0 (C0-2 and C0-6), 123.8 (C-5), 126.2
(CH‚CH), 130.4 (C-4), 132.1 (C0-3 and C0-5), 133.5 (C-
6), 133.9 (CH‚CH), 138.2 (C0-4), 148.6 (C000-5), 149.4 (C-
8), 154.8 (C000-2), 156.0 (C0-1), 166.4 (C-3), 166.9 (C-2),
192.3 (C‚O). MS (EI): m/z 441 [M+]. Anal. Cald for
C26H23N3O4: C, 70.73; H, 5.25; N, 9.52. Found: C, 70.88;
H, 5.23; N, 9.50.
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substitutedisoxazol-3-yl)phenylimino) indolin-2-one (6a–6j)
To a mixture of 1-(morpholinomethyl)-3-(4-(3-substitutedac-
ryloyl)phenylimino) indolin-2-one 5a–5j (0.05 mol) in ethanol
(20 ml), hydroxylamine hydrochloride (0.05 mol) was added.
To this catalytic quantity of sodium acetate glacial acetic acid
was added. Then the reaction mixture was stirred and reﬂuxed
for 10 h. The resulting mixture was cooled and poured in ice
cold water. The obtained product was ﬁltered, dried and
recrystallised using ethanol.
2.1.6.1. 1-(Morpholinomethyl)-3-(4-(5-phenylisoxazol-3-yl)
phenylimino)indolin-2-one (6a). Yield 71%, m.p. 261–
263 C. IR (KBr cm1): 3024 (ArACH), 1712 (C‚O), 1620
(C‚N), 1085 (CAOAC). 1H NMR (CDCl3, 300 MHz) d
ppm: 2.53–2.80 (t, 4H, CH2 of morpholine), 2.95–3.88 (t,
4H, CH2 of morpholine), 4.82 (s, 2H, NCH2N), 6.39 (s,
1H, CH of isoxazole), 7.26–8.14 (m, 13H, ArACH). 13C
NMR (CDCl3, 300 MHz) d ppm: 52.4 (C00-2 and C00-6),
65.7 (C00-3 and C00-5), 72.0 (CH2), 94.1 (C000-4), 118.5 (C-9),
120.9 (C-7), 124.2 (C0-2 and C0-6), 124.6 (C-5), 128.3 (C00 00-2
and C00 00-6), 129.5 (C00 00-4), 130.7 (C0-3 and C0-5), 131.0 (C00 00-
3 and C00 00-5), 131.5 (C-4), 132.2 (C00 00-1), 133.1 (C-6), 131.8
(C0-4), 145.3 (C-8), 153.6 (C0-1), 163.4 (C000-3), 164.2 (C-3),
164.9 (C-2), 172.0 (C000-5). MS (EI): m/z 464 [M+]. Anal. Cald
for C28H24N4O3: C, 72.40; H, 5.21; N, 12.06. Found: C,
72.65; H, 5.19; N, 12.02.
2.1.6.2. 1-(Morpholinomethyl)-3-(4-(5-p-tolylisoxazol-3-yl)
phenylimino)indolin-2-one (6b). Yield 79%, m.p. 289–291 C.
IR (KBr cm1): 2995 (ArACH), 2904 (CH3ACH), 1758
(C‚O), 1540 (C‚N), 1062 (CAOAC). 1H NMR (CDCl3,
300 MHz) d ppm: 1.91–2.74 (t, 4H, CH2 of morpholine),
3.18 (s, 3H, CH3), 3.40–3.96 (t, 4H, CH2 of morpholine),
4.50 (s, 2H, NCH2N), 6.23 (s, 1H, CH of isoxazole), 6.99–
7.82 (m, 12H, ArACH). 13C NMR (CDCl3, 300 MHz) d
ppm: 27.6 (CH3), 50.5 (C
00-2 and C00-6), 67.1 (C00-3 and C00-5),
71.9 (CH2), 97.3 (C
000-4), 117.0 (C-9), 122.6 (C-7), 123.4 (C0-2
and C0-6), 125.8 (C-5), 126.2 (C00 00-2 and C00 00-6), 126.7 (C00 00-
1), 129.3 (C0-3 and C0-5), 130.6 (C-4), 131.1 (C00 00-3 and C00 00-
5), 132.5 (C-6), 132.9 (C0-4), 137.2 (C00 00-4), 148.0 (C-8), 152.4
(C0-1), 161.7 (C000-3), 163.5 (C-3), 164.0 (C-2), 170.8 (C000-5).
MS (EI): m/z 478 [M+]. Anal. Cald for C29H26N4O3: C,
72.79; H, 5.48; N, 11.71. Found: C, 73.00; H, 5.46; N, 11.68.
2.1.6.3. 1-(Morpholinomethyl)-3-(4-(5-(4-nitrophenyl)iso-
xazol-3-yl)phenylimino)indolin-2-one (6c). Yield 70%, m.p.
254–256 C. IR (KBr cm1): 3032 (ArACH), 1727 (C‚O),
1575 (C‚N), 1526 and 1320 (NO2), 1068 (CAOAC).
1H
NMR (CDCl3, 300 MHz) d ppm: 2.17–2.95 (t, 4H, CH2 of
morpholine), 3.12–3.68 (t, 4H, CH2 of morpholine), 4.77 (s,
2H, NCH2N), 6.56 (s, 1H, CH of isoxazole), 7.31–8.20 (m,
12H, ArACH). 13C NMR (CDCl3, 300 MHz) d ppm: 52.9
(C00-2 and C00-6), 68.3 (C00-3 and C00-5), 69.0 (CH2), 99.6 (C000-
4), 120.2 (C-9), 122.8 (C00 00-3 and C00 00-5), 123.0 (C-7), 124.1
(C0-2 and C0-6), 124.7 (C-5), 129.5 (C00 00-2 and C00 00-6), 129.9
(C0-3 and C0-5), 130.2 (C-4), 131.6 (C-6), 133.0 (C0-4), 137.3
(C00 00-1), 149.1 (C-8), 150.6 (C00 00-4), 154.4 (C0-1), 163.9 (C000-3),
164.7 (C-3), 165.1 (C-2), 172.5 (C000-5). MS (EI): m/z 509
[M+]. Anal. Cald for C28H23N5O5: C, 66.00; H, 4.55; N,
13.75. Found: C, 66.17; H, 4.54; N, 13.71.2.1.6.4. 3-(4-(5-(4-Methoxyphenyl)isoxazol-3-yl)phenylimi-
no)-1-(morpholinomethyl) indolin-2-one (6d). Yield 73%,
m.p. 282–284 C. IR (KBr cm1): 3058 (ArACH), 2937
(CH3ACH), 1765 (C‚O), 1562 (C‚N), 1056 (CAOAC).
1H
NMR (CDCl3, 300 MHz) d ppm: 2.37–3.25 (t, 4H, CH2 of
morpholine), 3.31 (s, 3H, OCH3), 3.53–3.98 (t, 4H, CH2 of
morpholine), 4.94 (s, 2H, NCH2N), 6.32 (s, 1H, CH of isoxaz-
ole), 7.07–7.96 (m, 12H, ArACH). 13C NMR (CDCl3,
300 MHz) d ppm: 49.7 (C00-2 and C00-6), 57.0 (OCH3), 67.4
(C00-3 and C00-5), 71.9 (CH2), 96.5 (C000-4), 110.3 (C00 00-3 and
C00 00-5), 114.8 (C-9), 120.6 (C-7), 122.0 (C00 00-1), 122.4 (C0-2
and C0-6), 123.9 (C-5), 130.2 (C00 00-2 and C00 00-6), 130.7 (C0-3
and C0-5), 131.2 (C-4), 131.9 (C-6), 132.5 (C0-4), 145.3 (C-8),
153.0 (C0-1), 158.8 (C00 00-4), 161.4 (C000-3), 163.5 (C-3), 163.9
(C-2), 169.0 (C000-5). MS (EI): m/z 494 [M+]. Anal. Cald for
C29H26N4O4: C, 70.43; H, 5.30; N, 11.33. Found: C, 70.61;
H, 5.32; N, 11.29.
2.1.6.5. 3-(4-(5-(4-Hydroxyphenyl)isoxazol-3-yl)phenylimi-
no)-1-(morpholinomethyl) indolin-2-one (6e). Yield 80%,
m.p. 268–270 C. IR (KBr cm1): 3502 (OH), 3013 (ArACH),
1719 (C‚O), 1537 (C‚N), 1054 (CAOAC). 1H NMR
(CDCl3, 300 MHz) d ppm: 2.03–2.83 (t, 4H, CH2 of morpho-
line), 3.15-3.74 (t, 4H, CH2 of morpholine), 4.46 (s, 2H, NCH2-
N), 5.49 (s, 1H, OH), 6.70 (s, 1H, CH of isoxazole), 7.18–8.03
(m, 12H, ArACH). 13C NMR (CDCl3, 300 MHz) d ppm: 51.5
(C00-2 and C00-6), 67.1 (C00-3 and C00-5), 70.8 (CH2), 98.0 (C000-4),
117.2 (C00 00-3 and C00 00-5), 118.7 (C-9), 122.1 (C-7), 122.8 (C0-2
and C0-6), 123.9 (C00 00-1), 125.3 (C-5), 127.3 (C0-3 and C0-5),
127.6 (C00 00-2 and C00 00-6), 130.0 (C-4), 132.4 (C-6), 132.9 (C0-
4), 148.1 (C-8), 155.6 (C0-1), 157.4 (C00 00-4), 162.5 (C000-3),
163.1 (C-3), 163.7 (C-2), 170.2 (C000-5). MS (EI): m/z 480
[M+]. Anal. Cald for C28H24N4O4: C, 69.99; H, 5.03; N,
11.66. Found: C, 69.81; H, 5.05; N, 11.68.
2.1.6.6. 3-(4-(5-(4-(Dimethylamino)phenyl)isoxazol-3-yl)phe-
nylimino)-1-(morpholino methyl)indolin-2-one (6f). Yield
72%, m.p. 239–241 C. IR (KBr cm1): 3075 (ArACH), 2913
(CH3ACH), 1731 (C‚O), 1558 (C‚N), 1070 (CAOAC).
1H
NMR (CDCl3, 300 MHz) d ppm: 2.25–3.19 (t, 4H, CH2 of
morpholine), 3.27 (s, 6H, N(CH3)2), 3.42–3.97 (t, 4H, CH2 of
morpholine), 4.61 (s, 2H, NCH2N), 6.45 (s, 1H, CH of isoxaz-
ole), 6.80–7.91 (m, 12H, ArACH). 13C NMR (CDCl3,
300 MHz) d ppm: 36.8 (N(CH3)2), 53.0 (C00-2 and C00-6), 68.3
(C00-3 and C00-5), 71.6 (CH2), 96.2 (C000-4), 113.5 (C00 00-3 and
C00 00-5), 118.4 (C-9), 120.7 (C00 00-1), 123.1 (C-7), 123.9 (C0-2
and C0-6), 125.1 (C-5), 129.8 (C00 00-2 and C00 00-6), 130.4 (C0-3
and C0-5), 130.7 (C-4), 132.1 (C-6), 132.5 (C0-4), 146.3 (C-8),
149.0 (C00 00-4), 152.8 (C0-1), 161.6 (C000-3), 163.5 (C-3), 163.8
(C-2), 174.3 (C000-5). MS (EI): m/z 507 [M+]. Anal. Cald for
C30H29N5O3: C, 70.99; H, 5.76; N, 13.80. Found: C, 70.75;
H, 5.78; N, 13.84.
2.1.6.7. 1-(Morpholinomethyl)-3-(4-(5-(3-nitrophenyl)iso-
xazol-3-yl)phenylimino)indolin-2-one (6g). Yield 74%, m.p.
246–248 C. IR (KBr cm1): 3023 (ArACH), 1711
(C‚O), 1641 (C‚N), 1514 and 1337 (NO2), 1094
(CAOAC). 1H NMR (CDCl3, 300 MHz) d ppm: 2.19–
2.72 (t, 4H, CH2 of morpholine), 2.90–3.62 (t, 4H, CH2
of morpholine), 4.33 (s, 2H, NCH2N), 6.50 (s, 1H, CH
of isoxazole), 7.28–8.05 (m, 12H, ArACH). 13C NMR
(CDCl3, 300 MHz) d ppm: 51.4 (C00-2 and C00-6), 67.2
120 G. Saravanan et al.(C00-3 and C00-5), 70.9 (CH2), 100.6 (C000-4), 115.3 (C-9),
118.1 (C00 00-4), 118.9 (C-7), 119.5 (C00 00-2), 123.0 (C0-2 and
C0-6), 126.2 (C-5), 128.7 (C0-3 and C0-5), 130.0 (C-4),
131.4 (C00 00-5), 132.8 (C-6), 133.0 (C00 00-1), 133.7 (C0-4),
135.3 (C00 00-6), 149.6 (C-8), 150.1 (C00 00-3), 154.5 (C0-1),
160.0 (C000-3), 163.9 (C-3), 164.2 (C-2), 167.8 (C000-5). MS
(EI): m/z 509 [M+]. Anal. Cald for C28H23N5O5: C,
66.00; H, 4.55; N, 13.75. Found: C, 65.79; H, 4.56; N,
13.80.
2.1.6.8. 3-(4-(5-(2-Chlorophenyl)isoxazol-3-yl)phenylimino)-
1-(morpholinomethyl)indolin-2-one (6h). Yield 78%, m.p.
293–295 C. IR (KBr cm1): 3080 (ArACH), 1747 (C‚O),
1542 (C‚N), 1076 (CAOAC), 739 (Cl). 1H NMR (CDCl3,
300 MHz) d ppm: 2.16–2.90 (t, 4H, CH2 of morpholine),
3.18–3.71 (t, 4H, CH2 of morpholine), 4.58 (s, 2H, NCH2N),
6.34 (s, 1H, CH of isoxazole), 6.95–7.99 (m, 12H, ArACH).
13C NMR (CDCl3, 300 MHz) d ppm: 52.0 (C00-2 and C00-6),
65.7 (C00-3 and C00-5), 71.2 (CH2), 99.4 (C000-4), 116.9 (C-9),
121.5 (C-7), 123.8 (C0-2 and C0-6), 125.1 (C-5), 128.6 (C00 00-5),
129.3 (C0-3 and C0-5), 129.8 (C00 00-6), 130.2 (C-4), 130.7 (C00 00-
3), 131.4 (C00 00-4), 131.9 (C-6), 132.0 (C0-4), 132.6 (C00 00-2),
137.3 (C00 00-1), 146.1 (C-8), 151.8 (C0-1), 163.5 (C000-3), 165.2
(C-3), 165.7 (C-2), 170.3 (C000-5). MS (EI): m/z 500 [M+2].
Anal. Cald for C28H23ClN4O3: C, 67.40; H, 4.65; N, 11.23.
Found: C, 67.62; H, 4.66; N, 11.19.
2.1.6.9. 1-(Morpholinomethyl)-3-(4-(5-styrylisoxazol-3-yl)-
phenylimino)indolin-2-one (6i). Yield 75%, m.p. 230–232 C.
IR (KBr cm1): 3024 (ArACH), 1711 (C‚O), 1596 (C‚N),
1083 (CAOAC). 1H NMR (CDCl3, 300 MHz) d ppm: 2.00–
2.67 (t, 4H, CH2 of morpholine), 2.85–3.41 (t, 4H, CH2 of
morpholine), 5.09 (s, 2H, NCH2N), 6.83 (s, 1H, CH of isoxaz-
ole), 7.52–8.37 (m, 13H, ArACH), 8.56–8.92 (m, 2H,
CH‚CH). 13C NMR (CDCl3, 300 MHz) d ppm: 50.9 (C00-2
and C00-6), 68.2 (C00-3 and C00-5), 72.6 (CH2), 103.1 (C000-4),
119.8 (C-9), 122.4 (C-7), 122.9 (CH‚CH), 123.5 (C0-2 and
C0-6), 124.2 (C-5), 128.0 (C00 00-2 and C00 00-6), 129.3 (C00 00-4),
130.6 (C00 00-3 and C00 00-5), 130.9 (C0-3 and C0-5), 131.5 (C-4),
132.3 (C-6), 132.8 (C0-4), 134.0 (CH‚CH), 136.2 (C00 00-1),
149.7 (C-8), 152.5 (C0-1), 160.4 (C000-3), 163.9 (C-3), 164.2 (C-
2), 167.6 (C000-5). MS (EI): m/z 490 [M+]. Anal. Cald for
C30H26N4O3: C, 73.45; H, 5.34; N, 11.42. Found: C, 73.67;
H, 5.32; N, 11.39.
2.1.6.10. 3-(4-(5-(Furan-2-yl)isoxazol-3-yl)phenylimino)-1-
(morpholinomethyl)indolin-2-one (6j). Yield 81%, m.p. 272–
274 C. IR (KBr cm1): 3092 (ArACH), 1715 (C‚O), 1539
(C‚N), 1072 (CAOAC). 1H NMR (CDCl3, 300 MHz) d
ppm: 2.06–2.81 (t, 4H, CH2 of morpholine), 2.97–3.63 (t,
4H, CH2 of morpholine), 4.42 (s, 2H, NCH2N), 6.57 (s, 1H,
CH of isoxazole), 6.80–7.19 (m, 3H, CH of furan), 7.33–8.28
(m, 8H, ArACH). 13C NMR (CDCl3, 300 MHz) d ppm: 52.4
(C00-2 and C00-6), 67.1 (C00-3 and C00-5), 69.6 (CH2), 99.0 (C000-
4), 104.7 (C00 00-4), 106.2 (C00 00-3), 116.5 (C-9), 122.3 (C-7),
124.1 (C0-2 and C0-6), 125.2 (C-5), 127.6 (C0-3 and C0-5),
130.3 (C-4), 131.8 (C-6), 132.1 (C0-4), 141.3 (C00 00-5), 148.5
(C-8), 154.0 (C0-1), 154.7 (C00 00-2), 160.4 (C000-5), 163.2 (C000-3),
164.5 (C-3), 164.9 (C-2). MS (EI): m/z 454 [M+]. Anal. Cald
for C26H22N4O4: C, 68.71; H, 4.88; N, 12.33. Found: C,
68.49; H, 4.87; N, 12.37.2.2. Pharmacology
All the synthesized compounds were evaluated for their antiep-
ileptic effects using male albino mice (Swiss, 18–25 g) and rat
(Wistar 100–150 g). The primary qualitative evaluations per-
formed in mice involved two epilepsy tests (MES: Maximal
Electroshock Seizure test and scPTZ: Subcutaneous pentylen-
etetrazole). Acute neurological toxicity induced by the com-
pounds in mice was assessed through a standardized rotorod
test. In the initial screening, candidate compounds were
screened for their antiepileptic potential through MES and
scPTZ models in mice at a dose level of 30, 100 and 300 mg/
kg by intraperitoneal (i.p.) route and the groups of mice are
tested at different time points (i.e., 0.5 and 4 h) post adminis-
tration of the test candidate. It is generally acknowledged that
the MES model, which uses an electrical stimulus, induces gen-
eralized tonic–clonic seizures. Through electrical induction, it
is used to help recognize those compounds which prevent sei-
zure spread. The scPTZ is a model where the myoclonic sei-
zures were induced by chemical induction. It helps in
identifying those compounds that might act by increasing the
seizure threshold. Each group consisted of six animals. The
animals maintained in colony cages at 25 ± 2 C, relative
humidity of 45–55%, under a 12 h light and dark cycle; were
fed standard animal feed.19 All the animals were acclimatized
for a week before use.
2.2.1. The maximal electroshock test (MES)
The MES is a model for generalized tonic–clonic seizures and
provides a hint of a compound’s ability to stop seizure spread
when all neuronal circuits in the brain are maximally active.
These seizures are extremely reproducible and are electro phys-
iologically reliable with human seizures. For the MES, a drop
of anesthetic and electrolyte solution (tetracaine hydrochloride
(0.5%) in saline (0.9%)) was applied to the eyes of individual
animal before to placement of the corneal electrodes. The elec-
trical stimulus in the MES test was 50 mA, 60 Hz, for mice and
150 mA, 60 Hz, for rats delivered for 0.2 s by an apparatus
similar to a previously reported method.20,21 Abolition of the
hindleg tonic extensor component of the seizure was used as
the endpoint. Mice are initially tested with different doses of
30, 100 and 300 mg/kg of test compound given by i.p. injection
at various intervals while rats are initially screened at a ﬁxed
dose of 30 mg/kg given by oral route.
2.2.2. The subcutaneous pentylenetetrazole seizure test (scPTZ)
Subcutaneous injection of the convulsant Pentylenetetrazole
produces clonic seizures in laboratory animals. The scPTZ test
detects the ability of test compounds to raise the seizure
threshold of an animal and thus protect it from exhibiting a
clonic seizure. Animals are pretreated with various doses of
the test compound given by i.p. injection. The dose of Penty-
lenetetrazole which induces convulsions in 97% of animals
(CD97: 85 mg/kg mice) is injected into a loose fold of skin in
the midline of the neck. The animals are placed in isolation
cages to minimize stress22 and observed for the next 30 min
for the presence or absence of a seizure. An episode of clonic
spasms, approximately 3–5 s, of the fore and/or hindlimbs,
jaws, or vibrissae is taken as the endpoint. Animals which do
not meet this criterion are considered protected.
Novel isatin derivatives 1212.2.3. Acute toxicity-minimal motor impairment
To assess a compound’s undesirable side effects (toxicity), ani-
mals are monitored for overt signs of impaired neurological or
muscular function. In mice, the rotorod23 procedure is used to
disclose minimal muscular impairment (MMI) or minimal neu-
rological impairment (MNI). When a mouse is placed on a rod
that rotates at a speed of 6 rpm, the animal canmaintain its equi-
librium for longperiods of time.The animal is considered toxic if
it falls off this rotating rod three times during a 1 min period. In
addition to MMI, animals may exhibit a circular or zigzag gait,
abnormal bodyposture and spread of the legs, tremors, hyperac-
tivity, lack of exploratory behavior, somnolence, stupor, cata-
lepsy, loss of placing response and changes in muscle tone.3. Results and discussion
3.1. Chemistry
The reaction sequence leading to the synthesis of novel isatin
derivatives 5a–5j and 6a–6j is outlined in Scheme 1. Initially




































Scheme 1 Reagents and conditions: (a) CCl3CH(OH)2, NH2OH. H
NH2C6H4COCH3, C2H5OH, reﬂux 6 h; (d) HCHO, morpholine, C2H
stirring, 4 h reﬂux; (f) NH2OH. HCl, C2H5OH, CH3COOH, CH3COOhydrochloride in aqueous sodium sulfate to form an isonitros-
oacetanilide 1 with a loss of 3 mol of hydrochloric acid and one
mole of water. In the subsequent step isatin 2 was synthesized
through cyclization reaction by treating isonitrosoacetanilide 1
with concentrated sulfuric acid. Isatin 2 was treated with
p-amino acetophenone to produce 3-(4-acetylphenylimi-
no)indolin-2-one 3 by a condensation reaction, which proceeds
selectively on the carbonyl group in position 3 of the isatin
ring. Further compound 3 was treated with formaldehyde
and secondary amines (morpholine) to synthesize 3-(4-acetyl-
phenylimino)-1-(morpholinomethyl)indolin-2-one 4 by the
Mannich reaction. In the pre ﬁnal step isatin Mannich base
analog was treated with different aromatic/heterocyclic alde-
hydes in the presence of sodium hydroxide to isolate a corre-
sponding Schiff base derivatives 5a–5j. Finally the Schiff
base analogs 5a–5j were treated with hydroxylamine hydro-
chloride in the presence of sodium acetate and glacial acetic
acid to obtain 6a–6j through simple ring closure reaction.
TLC was performed throughout the reactions to optimize
the reactions for purity and completion.
The structures of the synthesized compounds were con-



































phenylimino)indolin-2-one (5a - 5j)
1-(Morpholinomethyl)-3-(4-(5-substitutedisoxazol-





Cl, 45 min heating; (b) H2SO4, heating at 80 C for 10 min; (c) 4-
5OH, 1 h stirring, 4 h reﬂux; (e) RCHO, C2H5OH, NaOH, 1 h
Na, 10 h reﬂux.
122 G. Saravanan et al.analyses data. IR, 1H NMR, mass and elemental analyses data
of the synthesized compounds are in accordance with the as-
signed structures. The IR spectrum of 5f displayed absorption
bands at 3061, 2947, 1749, 1554 and 1056 cm1 which was as-
signed to ArACH, CH3ACH, C‚O, C‚N and CAO-C vibra-
tions respectively. Also, its 1H NMR spectrum showed double
doublet at d 8.20–8.47 ppm for two protons of CH‚CH which
conﬁrms the formation of 5f. It also showed the following
other signals in its 1H NMR spectrum at d ppm 1.87–2.59 (t,
4H, CH2 of morpholine), 3.04 (s, 6H, N(CH3)2), 3.20–3.85 (t,
4H, CH2 of morpholine), 4.32 (s, 2H, NCH2N) and 7.19–
8.06 (m, 12H, ArACH) which supports the allotted structure
of 5f. Similarly IR spectrum of 6f displayed absorption bands
at 3075, 2913, 1731, 1558 and 1070 cm1 which were assigned
to ArACH, CH3ACH, C‚O, C‚N and CAOAC vibrations
respectively. Appearance of a singlet for one proton of isoxaz-
ole (C-4) at d 6.45 ppm conﬁrms the formation of compound
6f. In addition the 1H NMR spectrum of compound 6f also
showed signals at following d ppm 2.25–3.19 (t, 4H, CH2 of
morpholine), 3.27 (s, 6H, N(CH3)2), 3.42–3.97 (t, 4H, CH2 of
morpholine), 4.61 (s, 2H, NCH2N), 6.80–7.91 (m, 12H,
ArACH) which further conﬁrms the assigned structure of 6f.
3.2. Pharmacology
For the identiﬁcation of antiepileptic activity in mice, test com-
pounds 5a–5j and 6a–6j were administered i.p. and challengedTable 1 Antiepileptic activity and neurotoxicity of compounds 5a–
Compound MESa screening scP
0.5 hd 4.0 hd 0.5
5a 300 –– 30
5b 300 300 ––
5c –– –– ––
5d 300 300 30
5e 100 –– 30
5f 100 300 30
5g –– –– ––
5h –– –– ––
5i 300 –– ––
5j –– 300 30
6a 100 300 30
6b 30 300 30
6c –– –– ––
6d 30 300 10
6e 30 30 10
6f 30 30 10
6g –– –– 30
6h 300 –– ––
6i 100 300 ––
6j 100 –– 30
Phenytoine 30 30 ND
Ethosuximidef ND ND 10
The sign –– (mdash) represents an absence of activity at maximum dose
ND – Not determined.
a Maximal electroshock test (administered intraperitoneally to mice at
b Subcutaneous pentylenetetrazole test (administered intraperitoneally t
c Neurotoxicity (administered intraperitoneally to mice at doses rangin
d Time of test after drug administration.
e Reference drug, data for phenytoin.15
f Reference drug, data for ethosuximide.16by maximal electroshock (MES) and subcutaneous pentylen-
etetrazole (scPTZ) seizure test. Compounds found to be active
in these seizure challenges are generally regarded to be signif-
icantly useful candidates in the treatment of partial, general-
ized and even absence seizures. The data regarding the
antiepileptic screening of all the compounds are reported in
Table 1.
3.2.1. The maximal electroshock test (MES)
Most of the isoxazole coupled isatin derivatives 6a–6j exhibited
moderate to good antiepileptic activity in the MES screening;
whereas acryloylphenylimino attached isatin derivatives 5a–5j
exhibited poor activity. Out of several tested compounds in
the electroshock investigation, four compounds 6b, 6d, 6e
and 6f were found to be signiﬁcantly active. Out of these four
compounds, 6e and 6f showed protection at the lowest dose of
30 mg/kg after 0.5 h and 4.0 h. Whereas, compounds 6b and 6d
displayed protection at the lowest dose of 30 mg/kg after 0.5 h.
But at a higher dose (300 mg/kg) compounds 6b and 6d contin-
ued to show the activity after 4.0 h indicating the fast onset as
well as long duration of action of these compounds. The hope-
ful activity of the compounds may be attributed to the substi-
tutions at C-5 of isoxazole. These compounds contain electron
donating groups such as methyl, methoxy, hydroxy and
dimethylamino group at the distal aryl ring attached to isoxaz-
ole. At a dose of 100 mg/kg, after 0.5 h compounds 5e, 5f, 6a,
6i and 6j showed protection indicating the ability of these5j and 6a–6j administered intraperitoneally to mice.
TZb screening NTc screening
hd 4.0 hd 0.5 hd 4.0 hd
0 –– 300 ––
300 –– 300
–– ND ND
0 –– 300 ––
0 300 –– ––




0 –– –– 300
0 –– –– ––
0 300 –– 300
300 ND ND
0 300 –– ––
0 300 300 300
0 300 –– ––
0 –– ND ND
–– ND ND
300 100 ––
0 –– –– 300
ND 100 100
0 300 –– ––
administered (300 mg/kg).
doses ranging from 30 to 300 mg/kg).
o mice at doses ranging from 30 to 300 mg/kg).
g from 30 to 300 mg/kg).
Novel isatin derivatives 123compounds to protect from seizures at a relatively lower dose.
These compounds except 5e and 6j were also active after 4.0 h
at 300 mg/kg dose.
3.2.2. The subcutaneous pentylenetetrazole seizure test (scPTZ)
Compounds that revealed protection in the scPTZ test repre-
senting the ability of a substance to increasing seizure thresh-
olds. Among the entire tested compounds in scPTZ test, 6d,
6e and 6f were found to be signiﬁcantly active at a dose of
100 mg/kg after 0.5 h and these compounds continued to show
activity after 4.0 h at 300 mg/kg dose. The above results were
equal to results obtained for ethosuximide which is recognized
as reference AEDs for this screen. Except 5c, 5g, 5i and 6h, rest
of the compounds 5a, 5b, 5d–5f, 5h, 5j, 6a–6c, 6g, 6i and 6j
were active at 300 mg/kg after 0.5 h and/or 4.0 h. It was ob-
served that in this method, the most active compound has an
electron releasing group substituted distal aryl ring at C-5 of
isoxazole resulting in increased antiepileptic activity.
Numerous compounds that are, 5a, 5b, 5d–5f, 5i, 5j, 6a, 6b
and 6d–6j showed activity in either MES or scPTZ model at
any one of the tested doses after 0.5 h. The study reveals that
75% of the compounds showed activity in MES screening,
whereas in the scPTZ test 80% of the compounds were active
at any one of the tested doses. This information revealed that
most of compounds possessed some scPTZ selectivity. In gen-
eral it was observed that the isoxazole coupled isatin deriva-
tives exhibited better activity than the corresponding
acryloylphenylimino attached isatin derivatives. This may be
because of the fact that isoxazole coupled isatin derivatives
are better ﬁtted into the receptor site.
3.2.3. Acute toxicity-minimal motor impairment
The neurotoxicity study revealed that the majority of the can-
didate compounds exhibited neurotoxicity at doses higher
than commonly prescribed drugs Phenytoin or Carbamaze-
pine [15]. But while evaluating antiepileptic compounds, sep-
aration between the antiepileptic and neurotoxic doses is
desirable. Due to its poor response in antiepileptic activity,
apart from 5c, 5g–5i, 6c, 6g and 6h, rest of all compounds
were screened for the neurotoxicity study. At 100 mg/kg dose
6i was found to be neurotoxic after 0.5 h. Compounds 5a, 5b,
5d, 5j, 6b, 6e, and 6j showed neurotoxicity at 300 mg/kg after
0.5 h and/or 4.0 h, whereas all other compounds 5e, 5f, 6a, 6d
and 6f were not found to be neurotoxic at the maximum
administered dose.Table 2 Antiepileptic activity and toxicity of compounds 6b, 6d, 6e
Compound MESa






a Maximal electroshock test (dose of 30 mg/kg was administrated. The
b Neurotoxicity (number of rats protected/number of rats tested).
c Time after drug administration.
d (-) No neurotoxicity at dose tested.
e Reference drug, data for phenytoin.153.2.4. Antiepileptic activity and toxicity of compounds 6b, 6d, 6e
and 6f administered orally (30 mg/kg) to rats
Ability to inhibit epilepsy when given by the oral route is a
valuable property of candidate antiepilepsy. This screen
discloses the time of onset, the approximate time of peak effect
(TPE) and the duration of antiepileptic activity or neurotox-
icity. We identiﬁed four compounds 6b, 6d, 6e and 6f from
the initial screen that were further evaluated for oral availabil-
ity using the MES acute seizure model and neurotoxicity in
rats at a dose of 30 mg/kg. The results obtained are presented
in Table 2.
From this information it was observed that the most active
compound is 6f which protected 100% (4/4) of rats at time
points 2 h and 4 h, 75% (3/4) at 1 h, 50% (2/4) at 1 h, and
25% (1/4) at 0.25 h. These molecules were more active and
showed a longer duration of satisfactory action than Phenyt-
oin. The other compound 6e was moderately effective in rat
MES oral screening and protected only 75% (3/4) of the tested
animals at the time points 2 h and 4 h respectively. Moreover
this compound protected 50% (2/4) of the tested animals at
0.5 h and 1 h respectively and 25% (1/4) of tested animals at
0.25 h. Compounds 6b and 6d were found to be least effective.
Compound 6b protected 50% (2/4) of the rats at 4 h and 25%
(1/4) of the rats at 2 h; whereas compound 6d protected 50%
(2/4) of the rats at 0.5 h and 25% (1/4) of the rats at 1 h. All
derivatives tested were non-neurotoxic when given orally.
The in vivo data in rats conﬁrmed absorption of compounds
from the gastrointestinal tract and also their penetration into
central nervous system. The inhibition of electrically induced
seizures that is characteristic for Phenytoin and Phenytoin-like
drugs may point out the inﬂuence of compounds on voltage
dependent Na+ channels as the most probable mechanism of
antiepileptic action.
3.2.5. Structural activity relationship
On correlating the structures of the title compounds with their
biological activity, it has been observed that, out of several tested
compounds isoxazole substituted isatin derivatives 6a–6j
showed better activity than the corresponding acryloylphenyli-
mino substituted isatin derivatives 5a–5j. The increases in anti-
epileptic activity of isoxazole substituted isatin derivatives may
be attributed to the presence of an extra electron donor atom
on the isoxazole ring (which is absent in acryloylphenylimino
substituted isatin derivatives) which might be accountable for
additional bonding with the binding site. Within the isoxazoleand 6f administered orally (30 mg/kg) to rats.
TOXb
1 hc 2 hc 4 hc
0/4 1/4 2/4 0/4 (-)d
1/4 0/4 0/4 0/4 (-)d
2/4 3/4 3/4 0/4 (-)d
3/4 4/4 4/4 0/4 (-)d
3/4 3/4 3/4 0/4 (-)d
data indicate: number of rats protected/number of rats tested).
124 G. Saravanan et al.derivatives compounds possessing electron releasing groups
exhibited higher antiepileptic activity than the compounds con-
taining an electron withdrawing group. However, the unsubsti-
tuted derivative exhibits moderate antiepileptic activity.
4. Conclusion
In summary, remembering the pharmacophoric pattern of clin-
ically active AEDs we have designed and synthesized novel in-
dole-2,3-dione derivatives. The structure of synthesized
compounds 5a–5j and 6a–6j satisﬁed all the pharmacophoric
structural requirements of AEDs. Entire title compounds were
screened for their antiepileptic activity byMES and scPTZmod-
el. The active compounds were also tested for its neurotoxicity.
Generally in this study, isoxazole substituted isatin derivatives
showed better activity than the corresponding acryloylphenyli-
mino substituted isatin derivatives. In addition electron donat-
ing groups containing the compound exhibited higher
antiepileptic activity than the electron withdrawing groups con-
taining compound. Out of several tested compounds the most
active one was 3-(4-(5-(4-(dimethylamino)phenyl)isoxazol-3-
yl)phenylimino)-1-(morpholinomethyl)indolin-2-one 6f that re-
vealed protection in the electrically induced seizures at a dose of
30 mg/kg (i.p.) after 0.5 h and 4 h. This molecule also provided
protection in the scPTZ at a dose of 100 mg/kg and 300 mg/kg
after 0.5 h and 4 h respectively. Moreover this compound also
exhibited better antiepileptic activity in the oral dose than the
standard drug Phenytoin. As a result the compound 6f emerged
out as the pilot molecule with a broad spectrum of antiepileptic
activity without any neurotoxicity.
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